Étiquette : cannabis

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users, Camilla Beale et al., 2018

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users Camilla Beale, Samantha J. Broyd, Yann Chye, Chao Suo, Mark Schira, Peter Galettis, Jennifer H. Martin, Murat Yücel and Nadia Solowij Cannabis and Cannabinoid Research, 2018, 3, 1, 94-107. Doi : 10.1089/can.2017.0047 Abstract Introduction : Chronic cannabis use is associated with neuroanatomical alterations in the hippocampus. While adverse impacts of cannabis use are generally attributed to D9 tetrahydro-cannabinol, emerging naturalistic evidence suggests cannabidiol (CBD) is neuroprotective and may ameliorate brain harms associated with cannabis use, including protection from hippocampal volume loss. This study examined whether prolonged administration of CBD to regular cannabis users [...]

Lire la suite

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder, Beth Wiese and Adrianne R. Wilson-Poe, 2018

Emerging Evidence for Cannabis’ Role in Opioid Use Disorder Beth Wiese and Adrianne R. Wilson-Poe Cannabis and Cannabinoid Research, 2018, Volume 3.1,179-189. Doi : 10.1089/can.2018.0022   Abstract Introduction : The opioid epidemic has become an immense problem in North America, and despite decades of research on the most effective means to treat opioid use disorder (OUD), overdose deaths are at an all-time high, and relapse remains pervasive. Discussion : Although there are a number of FDA-approved opioid replacement therapies and maintenance medications to help ease the severity of opioid withdrawal symptoms and aid in relapse prevention, these medications are not risk free nor are they successful for [...]

Lire la suite

No Link Between Marijuana Use and Cancer, Except TGCT, Nick Mulcahy, 2019

No Link Between Marijuana Use and Cancer, Except TGCT Nick Mulcahy Medscape Psychiatry, November 27, 2019 https://www.medscape.com/viewarticle/921889?nlid=132907_2052&src=WNL_mdplsnews_191206_mscpedit_psyc&uac=292598PZ&spon=12&impID=2194053&faf=1 More than 10 years of marijuana use is associated with the development of testicular germ cell tumor (TGCT), but the quality of the evidence is "low strength" and there is insufficient evidence to support an association between ever having used marijuana and other types of cancer. These are the conclusions from a new systematic review and meta-analysis published online today in JAMA Open Network. Lead author Mehrnaz Ghasemiesfe, MD, Northern California Institute of Research and Education, San Francisco, and colleagues explain that they wondered if marijuana smoke might cause [...]

Lire la suite

CBD Oil : An Introduction, Zoe Sigman, 2019

CBD Oil: An Introduction Zoe Sigman 2019 https://www.projectcbd.org/cbd-101/what-is-cbd-oil   Medical patients swear by it. Researchers are intrigued by it. Government regulators are flustered by it. And investors are head over heels for it. CBD oil is the It-Medicine of the moment. A few years ago, hardly anyone knew about CBD oil. Today there’s a huge demand for it. Millions of people are taking CBD oil as a health supplement. But what exactly is it? Where does it come from? How is it made? And what should you know before you buy it? Where Does CBD Oil Come From ? Cannabidiol (CBD) is one of more than 100 unique “cannabinoid” [...]

Lire la suite

CBD & Cannabis Dosage Guide, Martin A. LEE, projectCBD.org, 2019

CBD & Cannabis Dosage Guide Martin A. Lee On May 16, 2018 (Updated on April 1, 2019) https://www.projectcbd.org/how-to/cbd-dosage-guide High dose? Low dose? CBD? THC? Optimizing one's therapeutic use of cannabis may take some experimentation. It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people. Smoking marijuana, however, is not the be-all and end-all of cannabis therapeutics. There are many ways to experience the medical benefits of cannabis, and some of them are even non-intoxicating. In recent years, the advent of potent cannabis oil concentrates, non-intoxicating cannabidiol (CBD) products, [...]

Lire la suite

Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone, Roberto Frau et al., 2019

Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone Roberto Frau, Vivien Miczán, Francesco Traccis, Sonia Aroni, Csaba I. Pongor, Pierluigi Saba, Valeria Serra, Claudia Sagheddu, Silvia Fanni, Mauro Congiu, Paola Devoto, Joseph F. Cheer, István Katona and Miriam Melis Nature Neuroscience,  December 2019, VOL 22, 1975–1985 www.nature.com/natureneuroscience1975 Content courtesy of Springer Nature, terms of use apply. Rights reserved Doi : 10.1038/s41593-019-0512-2 The increased legal availability of cannabis has led to a common misconception that it is a safe natural remedy for, among others, pregnancy-related ailments such as morning sickness. Emerging clinical evidence, however, indicates that prenatal cannabis exposure (PCE) predisposes offspring to various neuropsychiatric [...]

Lire la suite

Cannabis Use in Adolescence : A Review of Neuroimaging Findings, Yann Chye et al., 2019

Cannabis Use in Adolescence : A Review of Neuroimaging Findings Yann Chye, Erynn Christensen & Murat Yücel Journal of Dual Diagnosis, 2019 Doi : 10.1080/15504263.2019.1636171   ABSTRACT Objective : Shifting policies and widespread acceptance of cannabis for medical and/or recreational purposes have fueled worries of increased cannabis initiation and use in adolescents. In particular, the adolescent period is thought to be associated with an increased susceptibility to the potential harms of repeated cannabis use, due to being a critical period for neuromaturational events in the brain. This review investigates the neuroimaging evidence of brain harms attributable to adolescent cannabis use. Methods : PubMed and Scopus searches were [...]

Lire la suite

Cannabis use and later life outcomes, David M. Fergusson & Joseph M. Boden, 2008

Cannabis use and later life outcomes David M. Fergusson & Joseph M. Boden Addiction, 2008, 103, 969–976 doi : 10.1111/j.1360-0443.2008.02221.x   ABSTRACT Aim : To examine the associations between the extent of cannabis use during adolescence and young adult-hood and later education, economic, employment, relationship satisfaction and life satisfaction outcomes. Design A longitudinal study of a New Zealand birth cohort studied to age 25 years. Measurements : Measures of : cannabis use at ages 14–25; university degree attainment to age 25; income at age 25; welfare dependence during the period 21–25 years; unemployment 21–25 years; relationship quality; life satisfaction. Also, measures of childhood socio-economic disadvantage, family adversity, [...]

Lire la suite

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse, Bertha K. Madras et al, 2019

Associations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse Bertha K. Madras, Beth Han, Wilson M. Compton, Christopher M. Jones, Elizabeth I. Lopez, Elinore F. McCance-Katz JAMA Network Open, 2019, 2, (11), e1916015. doi : 10.1001/jamanetworkopen.2019.16015   Abstract IMPORTANCE : Marijuana use is increasing among adults and often co-occurs with other substance use; therefore, it is important to examine whether parental marijuana use is associated with elevated risk of substance use among offspring living in the same household. OBJECTIVE : To examine associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. DESIGN, SETTING, AND PARTICIPANTS : [...]

Lire la suite

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia, Jan van Amsterdam et al., 2018

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia Jan van Amsterdam, Jojanneke Vervloet, Gerdien de Weert, Victor J. A. Buwalda, Anna E. Goudriaan and Wim van den Brink Harm Reduction Journal, 2018, 15, 47, 1-4. Doi : 10.1186/s12954-018-0253-7   Abstract Background : Cannabis-smoking patients with a psychotic disorder have poorer disease outcomes than non-cannabis-smoking patients with poorest outcomes in patients smoking high-potency cannabis (HPC) containing high Δ9-tetrahydrocannabinol (THC) and low cannabidiol (CBD). Quitting cannabis smoking or substitution of HPC by cannabis variants containing less THC and/or more CBD may benefit these patients. The present study explores whether daily HPC-smoking patients with schizophrenia accept smoking [...]

Lire la suite